1,193 research outputs found
Recommended from our members
Hyperlipidemia as an Instigator of Inflammation: Inaugurating New Approaches to Vascular Prevention
Inflammation and Atherothrombosis: Where Have We Been? Where Are We Going? Why Perform the CIRT and CANTOS Trials? From Bench to Bedside to Population and Back: A Story of Clinical Translation
Discussion of clinical and translational science in the context of Dr. Ridker\u27s research on inflammation, atherothrombosis, and cardiovascular disease prevention
Recommended from our members
Are Statins Anti-Inflammatory?
Large scale clinical trials demonstrate significant reductions in cardiovascular event rates with statin therapy. The observed benefit of statin therapy, however, may be larger in these trials than that expected on the basis of lipid lowering alone. Emerging evidence from both clinical trials and basic science studies suggest that statins have anti-inflammatory properties, which may additionally lead to clinical efficacy. Measurement of markers of inflammation such as high sensitivity C-reactive protein in addition to lipid parameters may help identify those patients who will benefit most from statin therapy
EFFICACY OF ROSUVASTATIN IN PRIMARY PREVENTION ACCORDING TO BASELINE LEVELS OF HSCRP IN THE JUPITER TRIAL
Inflammation, Coronary Flow Reserve, and Microvascular Dysfunction Moving Beyond Cardiac Syndrome X∗
Projected life-expectancy gains with statin therapy for individuals with elevated c-reactive protein levels
AbstractObjectivesWe sought to estimate the potential gains in life expectancy achieved with statin therapy for individuals without overt hyperlipidemia but with elevated C-reactive protein (CRP) levels.BackgroundPersons with low-density lipoprotein (LDL) cholesterol levels below current treatment guidelines and elevated CRP levels are at increased risk of cardiovascular disease and may benefit from statin therapy.MethodsWe constructed a decision-analytic model to estimate the gains in life expectancy with statin therapy for individuals without overt hyperlipidemia but with elevated CRP levels. The annual risks of myocardial infarction (MI) and stroke, as well as the efficacy of statin therapy, were based on evidence from randomized trials. Estimates of prognosis after MI or stroke were derived from population-based studies.ResultsWe estimated that 58-year-old men and women with CRP levels ≥0.16 mg/dl but LDL cholesterol <149 mg/dl would gain 6.6 months and 6.4 months of life expectancy, respectively, with statin therapy. These gains were similar to those for patients with LDL cholesterol ≥149 mg/dl (6.7 months for men and 6.6 months for women). In sensitivity analyses, we identified the baseline risk of MI and the efficacy of statin therapy for preventing MI as the most important factors in determining the magnitude of benefit with statin therapy.ConclusionsOur results suggest that individuals with elevated CRP levels, many of whom do not meet current National Cholesterol Education Program guidelines for drug treatment, may receive a substantial benefit from statin therapy. This analysis supports a crucial need for direct intervention trials aimed at subjects with elevated CRP levels
ATHEROGENIC LIPOPROTEIN PARTICLE SUBCLASSES AND RESIDUAL CARDIOVASCULAR RISK: AN ANALYSIS OF THE JUPITER TRIAL
Impact of sepsis on risk of postoperative arterial and venous thromboses: large prospective cohort study
Objectives: To evaluate the impact of preoperative sepsis on risk of postoperative arterial and venous thromboses. Design: Prospective cohort study using the National Surgical Quality Improvement Program database of the American College of Surgeons (ACS-NSQIP). Setting: Inpatient and outpatient procedures in 374 hospitals of all types across the United States, 2005-12. Participants: 2 305 380 adults who underwent surgical procedures. Main outcome measures Arterial thrombosis (myocardial infarction or stroke) and venous thrombosis (deep venous thrombosis or pulmonary embolism) in the 30 days after surgery. Results: Among all surgical procedures, patients with preoperative systemic inflammatory response syndrome or any sepsis had three times the odds of having an arterial or venous postoperative thrombosis (odds ratio 3.1, 95% confidence interval 3.0 to 3.1). The adjusted odds ratios were 2.7 (2.5 to 2.8) for arterial thrombosis and 3.3 (3.2 to 3.4) for venous thrombosis. The adjusted odds ratios for thrombosis were 2.5 (2.4 to 2.6) in patients with systemic inflammatory response syndrome, 3.3 (3.1 to 3.4) in patients with sepsis, and 5.7 (5.4 to 6.1) in patients with severe sepsis, compared with patients without any systemic inflammation. In patients with preoperative sepsis, both emergency and elective surgical procedures had a twofold increased odds of thrombosis. Conclusions: Preoperative sepsis represents an important independent risk factor for both arterial and venous thromboses. The risk of thrombosis increases with the severity of the inflammatory response and is higher in both emergent and elective surgical procedures. Suspicion of thrombosis should be higher in patients with sepsis who undergo surgery
- …